{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T02:41:56Z","timestamp":1788921716391,"version":"build-2803163510"},"reference-count":61,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2019,12,24]],"date-time":"2019-12-24T00:00:00Z","timestamp":1577145600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"WG Pharmacotherapy of the ESC"},{"DOI":"10.13039\/501100014835","name":"IRCCS","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100014835","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Benefits and safety on statins have been well-established over 20\u2009years of research. Despite this, the vast majority of patients are not adequately treated and do not achieve the low-density lipoprotein cholesterol target levels. This is mainly due to poor adherence, which is associated with dangerous and sometimes fatal outcomes. To increase adherence and prevent worse outcomes, a combination therapy with lower dosage of statins and new lipid-lowering drugs may be used. However, the implementation of new lipid-lowering drugs in European countries is still at the beginning. For these reasons, the aim of this position paper is to give an up-to-date indication from the ESC Working Group on Cardiovascular Pharmacotherapy in order to discuss the barriers towards statins adherence and new lipid-lowering drugs implementation in Europe.<\/jats:p>","DOI":"10.1093\/ehjcvp\/pvz079","type":"journal-article","created":{"date-parts":[[2019,12,20]],"date-time":"2019-12-20T15:11:28Z","timestamp":1576854688000},"page":"115-121","source":"Crossref","is-referenced-by-count":66,"title":["An expert opinion paper on statin adherence and implementation of new lipid-lowering medications by the ESC Working Group on Cardiovascular Pharmacotherapy: Barriers to be overcome"],"prefix":"10.1093","volume":"6","author":[{"given":"Heinz","family":"Drexel","sequence":"first","affiliation":[{"name":"Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT), Feldkirch, Austria"},{"name":"Division of Angiology, Swiss Cardiovascular Center, University Hospital of Bern, Bern, Switzerland"},{"name":"Private University of the Principality of Liechtenstein, Triesen, Liechtenstein"},{"name":"Drexel University College of Medicine, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J S","family":"Coats","sequence":"additional","affiliation":[{"name":"University of Warwick, Coventry CV4 7AL, UK"},{"name":"Monash University, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8135-7479","authenticated-orcid":false,"given":"Ilaria","family":"Spoletini","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Centre for Clinical and Basic Research, IRCCS San Raffaele Pisana, Via della Pisana, 235, 00163 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Bilato","sequence":"additional","affiliation":[{"name":"Division of Cardiology, West Vicenza General Hospitals, Vicenza, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Mollace","sequence":"additional","affiliation":[{"name":"Institute for Food Safety & Health University, \u2018Magna Graecia of Catanzaro\u2019, Catanzaro, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasquale","family":"Perrone Filardi","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Advanced Biomedical Sciences, University of Naples Federico II, Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe M C","family":"Rosano","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Centre for Clinical and Basic Research, IRCCS San Raffaele Pisana, Via della Pisana, 235, 00163 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,12,24]]},"reference":[{"key":"2020091315341379900_pvz079-B1","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90, 056 participants in 14 randomised trials of statins","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"},{"key":"2020091315341379900_pvz079-B2","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1016\/j.jacc.2013.11.002","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"63","author":"Stone","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2020091315341379900_pvz079-B3","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1056\/NEJMoa1600177","article-title":"Blood-pressure and cholesterol lowering in persons without cardiovascular disease","volume":"374","author":"Yusuf","year":"2016","journal-title":"N Engl J Med"},{"key":"2020091315341379900_pvz079-B4","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.atherosclerosis.2016.08.018","article-title":"ESC\/EAS Guidelines for the Management of Dyslipidaemias: the Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR)","volume":"253","author":"Catapano","year":"2016","journal-title":"Atherosclerosis"},{"key":"2020091315341379900_pvz079-B5","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1093\/eurheartj\/ehu107","article-title":"The ACC\/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC\/EAS guidelines for the management of dyslipidaemias 2011","volume":"35","author":"Ray","year":"2014","journal-title":"Eur Heart J"},{"key":"2020091315341379900_pvz079-B6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1161\/JAHA.117.006460","article-title":"Lipid testing and statin dosing after acute myocardial infarction","volume":"7","author":"Wang","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"2020091315341379900_pvz079-B7","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.jacc.2014.09.088","article-title":"Underutilization of high-intensity statin therapy after hospitalization for coronary heart disease","volume":"65","author":"Rosenson","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2020091315341379900_pvz079-B8","first-page":"2473","article-title":"Comprehensive efforts to increase adherence to statin therapy","volume":"38","author":"Vonbank","year":"2017","journal-title":"Eur Heart J"},{"key":"2020091315341379900_pvz079-B9","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1111\/j.1525-1497.2004.30516.x","article-title":"Suboptimal statin adherence and discontinuation in primary and secondary prevention populations","volume":"19","author":"Ellis","year":"2004","journal-title":"J Gen Intern Med"},{"key":"2020091315341379900_pvz079-B10","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1093\/eurheartj\/ehi705","article-title":"Long-term compliance with beta-blockers, angiotensin-converting enzyme inhibitors, and statins after acute myocardial infarction","volume":"27","author":"Gislason","year":"2006","journal-title":"Eur Heart J"},{"key":"2020091315341379900_pvz079-B11","first-page":"w13828.","article-title":"Current cholesterol guidelines and clinical reality: a comparison of two cohorts of coronary artery disease patients","volume":"143","author":"Vonbank","year":"2013","journal-title":"Swiss Med Wkly"},{"key":"2020091315341379900_pvz079-B12","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.atherosclerosis.2019.03.014","article-title":"Management of dyslipidaemia in patients with coronary heart disease: results from the ESC-EORP EUROASPIRE V survey in 27 countries","volume":"285","author":"De Backer","year":"2019","journal-title":"Atherosclerosis"},{"key":"2020091315341379900_pvz079-B13","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.jacc.2016.12.036","article-title":"Statin intolerance and risk of coronary heart events and all-cause mortality following myocardial infarction","volume":"69","author":"Serban","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2020091315341379900_pvz079-B14","volume-title":"Compliance in Health Care","author":"Haynes","year":"1979"},{"key":"2020091315341379900_pvz079-B15","first-page":"103","article-title":"New findings about patient adherence to prescribe drug dosing regimes","volume":"103","author":"Urquhart","year":"2005","journal-title":"Eur J Hosp Pharm Sci"},{"key":"2020091315341379900_pvz079-B16","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1524-4733.2007.00213.x","article-title":"Medication compliance and persistence: terminology and definitions","volume":"11","author":"Cramer","year":"2008","journal-title":"Value Health"},{"key":"2020091315341379900_pvz079-B17","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1056\/NEJMra050100","article-title":"Adherence to medication","volume":"353","author":"Osterberg","year":"2005","journal-title":"N Engl J Med"},{"key":"2020091315341379900_pvz079-B18","volume-title":"Adherence to Long-Term Therapies: Evidence for Action","year":"2003"},{"key":"2020091315341379900_pvz079-B19","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1001\/archinte.167.16.1798","article-title":"Self-reported medication adherence and cardiovascular events in patients with stable coronary heart disease: the heart and soul study","volume":"167","author":"Gehi","year":"2007","journal-title":"Arch Intern Med"},{"key":"2020091315341379900_pvz079-B20","doi-asserted-by":"crossref","first-page":"15.","DOI":"10.1136\/bmj.38875.675486.55","article-title":"A meta-analysis of the association between adherence to drug therapy and mortality","volume":"333","author":"Simpson","year":"2006","journal-title":"BMJ"},{"key":"2020091315341379900_pvz079-B21","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1592\/phco.2005.25.8.1035","article-title":"Cardiovascular morbidity associated with nonadherence to statin therapy","volume":"25","author":"Blackburn","year":"2005","journal-title":"Pharmacotherapy"},{"key":"2020091315341379900_pvz079-B22","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1111\/bcp.12339","article-title":"Impact of statin adherence on cardiovascular disease and mortality outcomes: a systematic review","volume":"78","author":"De Vera","year":"2014","journal-title":"Br J Clin Pharmacol"},{"key":"2020091315341379900_pvz079-B23","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jacl.2008.01.002","article-title":"Misperception among physicians and patients regarding the risks and benefits of statin treatment: the potential role of direct-to-consumer advertising","volume":"2","author":"Kon","year":"2008","journal-title":"J Clin Lipidol"},{"key":"2020091315341379900_pvz079-B24","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1001\/jama.288.4.462","article-title":"Adherence with statin therapy in elderly patients with and without acute coronary syndromes","volume":"288","author":"Jackevicius","year":"2002","journal-title":"JAMA"},{"key":"2020091315341379900_pvz079-B25","doi-asserted-by":"crossref","first-page":"484","DOI":"10.5414\/CPP44484","article-title":"Factors associated with healthcare utilization costs for statin therapy\u2014a pilot study in Hong Kong","volume":"44","author":"Cheng","year":"2006","journal-title":"Int J Clin Pharmacol Ther"},{"key":"2020091315341379900_pvz079-B26","doi-asserted-by":"crossref","first-page":"e0191817.","DOI":"10.1371\/journal.pone.0191817","article-title":"Patient-reported adherence to statin therapy, barriers to adherence, and perceptions of cardiovascular risk","volume":"13","author":"Fung","year":"2018","journal-title":"PLoS One"},{"key":"2020091315341379900_pvz079-B27","first-page":"1386","article-title":"Underutilization of high-intensity statin therapy after hospitalization for coronary heart disease statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management","volume":"69","author":"Stroes","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2020091315341379900_pvz079-B28","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1002\/jcsm.12344","article-title":"Introducing the \u2018Drucebo\u2019 effect in statin therapy: a systematic review of studies comparing reported rates of statin-associated musclesymptoms, under blinded and open-label conditions","volume":"9","author":"Penson","year":"2018","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"2020091315341379900_pvz079-B29","doi-asserted-by":"crossref","first-page":"e016604.","DOI":"10.1136\/bmjopen-2017-016604","article-title":"Study protocol for statin web-based investigation of side effects (StatinWISE): a series of randomised controlled N-of-1 trials comparing atorvastatin and placebo in UK primary care","volume":"7","author":"Herrett","year":"2017","journal-title":"BMJ Open"},{"key":"2020091315341379900_pvz079-B30","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events","volume":"372","author":"Robinson","year":"2015","journal-title":"N Engl J Med"},{"key":"2020091315341379900_pvz079-B31","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1016\/S0140-6736(16)31357-5","article-title":"Interpretation of the evidence for the efficacy and safety of statin therapy","volume":"388","author":"Collins","year":"2016","journal-title":"Lancet"},{"key":"2020091315341379900_pvz079-B32","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0140-6736(18)31942-1","article-title":"Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials","volume":"393","year":"2019","journal-title":"Lancet"},{"key":"2020091315341379900_pvz079-B33","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1080\/17512433.2018.1412826","article-title":"Adhering to the principles of clinical pharmacology - the correct fixed combinations of antihypertensive drugs","volume":"11","author":"Lopatowska","year":"2018","journal-title":"Expert Rev Clin Pharmacol"},{"key":"2020091315341379900_pvz079-B34","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"key":"2020091315341379900_pvz079-B35","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jacl.2015.08.006","article-title":"Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: the ODYSSEY ALTERNATIVE randomized trial","volume":"9","author":"Moriarty","year":"2015","journal-title":"J Clin Lipidol"},{"key":"2020091315341379900_pvz079-B36","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1001\/jama.2016.3608","article-title":"Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3 randomized clinical trial","volume":"315","author":"Nissen","year":"2016","journal-title":"JAMA"},{"key":"2020091315341379900_pvz079-B37","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.amjcard.2011.03.079","article-title":"Safety and efficacy of ezetimibe added on to rosuvastatin 5 or 10 mg versus up-titration of rosuvastatin in patients with hypercholesterolemia (the ACTE Study)","volume":"108","author":"Bays","year":"2011","journal-title":"Am J Cardiol"},{"key":"2020091315341379900_pvz079-B38","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.clinthera.2017.12.018","article-title":"A phase III, multicenter, randomized, double-blind, active comparator clinical trial to compare the efficacy and safety of combination therapy with ezetimibe and rosuvastatin versus rosuvastatin monotherapy in patients with hypercholesterolemia: I-ROSETTE (Ildong Rosuvastatin & Ezetimibe for Hypercholesterolemia) Randomized Controlled Trial","volume":"40","author":"Hong","year":"2018","journal-title":"Clin Ther"},{"key":"2020091315341379900_pvz079-B39","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ijcard.2017.02.099","article-title":"A randomized, controlled comparison of different intensive lipid-lowering therapies in Chinese patients with non-ST-elevation acute coronary syndrome (NSTE-ACS): ezetimibe and rosuvastatin versus high-dose rosuvastatin","volume":"235","author":"Ran","year":"2017","journal-title":"Int J Cardiol"},{"key":"2020091315341379900_pvz079-B40","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.jacc.2016.11.070","article-title":"Atherothrombotic risk stratification and ezetimibe for secondary prevention","volume":"69","author":"Bohula","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2020091315341379900_pvz079-B41","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1161\/CIRCULATIONAHA.117.030950","article-title":"Braunwald E; IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) Investigators. Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)","volume":"137","author":"Giugliano","year":"2018","journal-title":"Circulation"},{"key":"2020091315341379900_pvz079-B42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1161\/JAHA.117.006901","article-title":"Efficacy and safety of adding ezetimibe to statin therapy among women and men: insight from IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)","volume":"6","author":"Kato","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"2020091315341379900_pvz079-B43","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1001\/jamacardio.2017.0083","article-title":"Long-term safety and efficacy of achieving very low levels of low-density lipoprotein cholesterol: a prespecified analysis of the IMPROVE-IT trial","volume":"2","author":"Giugliano","year":"2017","journal-title":"JAMA Cardiol"},{"key":"2020091315341379900_pvz079-B44","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1001\/archinte.165.10.1147","article-title":"Predictors of adherence with antihypertensive and lipid-lowering therapy","volume":"165","author":"Chapman","year":"2005","journal-title":"Arch Intern Med"},{"key":"2020091315341379900_pvz079-B45","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1007\/s12325-017-0560-5","article-title":"Advances in clinical cardiology 2016: a summary of the key clinical trials","volume":"34","author":"Gray","year":"2017","journal-title":"Adv Ther"},{"key":"2020091315341379900_pvz079-B46","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/17425255.2018.1416094","article-title":"Pharmacokinetics, pharmacodynamics and clinical efficacy of non-statintreatments for hypercholesterolemia","volume":"14","author":"Cicero","year":"2018","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"2020091315341379900_pvz079-B47","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1056\/NEJMoa1701131","article-title":"Cognitive function in a randomized trial of evolocumab","volume":"377","author":"Giugliano","year":"2017","journal-title":"N Engl J Med"},{"key":"2020091315341379900_pvz079-B48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1161\/JAHA.117.006910","article-title":"Effect of PCSK9 inhibitors on clinical outcomes in patients with hypercholesterolemia: a meta-analysis of 35 randomized controlled trials","volume":"6","author":"Karatasakis","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"2020091315341379900_pvz079-B49","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"; FOURIER Steering Committee and Investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"2020091315341379900_pvz079-B50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1161\/JAHA.116.005367","article-title":"Systematic review and network meta-analysis on the efficacy of evolocumab and other therapies for the management of lipid levels in hyperlipidemia","volume":"6","author":"Toth","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"2020091315341379900_pvz079-B51","doi-asserted-by":"crossref","first-page":"3588","DOI":"10.1093\/eurheartj\/ehw388","article-title":"Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial","volume":"37","author":"Moriarty","year":"2016","journal-title":"Eur Heart J"},{"key":"2020091315341379900_pvz079-B52","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1111\/dom.12909","article-title":"Lipid-lowering efficacy and safety of alirocumab in patients with or without diabetes: a sub-analysis of ODYSSEY COMBO II","volume":"19","author":"Leiter","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"2020091315341379900_pvz079-B53","doi-asserted-by":"crossref","first-page":"282","DOI":"10.5551\/jat.45070","article-title":"Efficacy and safety of alirocumab in Japanese patients with diabetes mellitus: post-hoc subanalysis of ODYSSEY Japan","volume":"26","author":"Teramoto","year":"2019","journal-title":"J Atheroscler Thromb"},{"key":"2020091315341379900_pvz079-B54","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.3904\/kjim.2018.133","article-title":"Efficacy and safety of alirocumab in Korean patients with hypercholesterolemia and high cardiovascular risk: subanalysis of the ODYSSEY-KT study","volume":"34","author":"Nam","year":"2019","journal-title":"Korean J Intern Med"},{"key":"2020091315341379900_pvz079-B55","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/j.jacc.2017.08.057","article-title":"The PCSK9-LDL receptor axis and outcomes in heart failure: BIOSTAT-CHF subanalysis","volume":"70","author":"Bayes-Genis","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2020091315341379900_pvz079-B56","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1001\/jama.2016.16951","article-title":"Effect of evolocumab on progression of coronary disease in statin treated patients: the GLAGOV randomized clinical trial","volume":"316","author":"Nicholls","year":"2016","journal-title":"JAMA"},{"key":"2020091315341379900_pvz079-B57","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.jacc.2018.10.039","article-title":"ODYSSEY OUTCOMES Committees and Investigators. Alirocumab reduces total nonfatal cardiovascular and fatal events: the ODYSSEY OUTCOMES trial","volume":"73","author":"Szarek","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2020091315341379900_pvz079-B58","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jacc.2018.04.040","article-title":"The role of nutraceuticals in statin intolerant patients","volume":"72","author":"Banach","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2020091315341379900_pvz079-B59","doi-asserted-by":"crossref","first-page":"73.","DOI":"10.1186\/1472-6882-11-73","article-title":"Effect of plant sterols on the lipid profile of patients with hypercholesterolaemia. Randomised, experimental study","volume":"11","author":"P\u00e1rraga","year":"2011","journal-title":"BMC Complement Altern Med"},{"key":"2020091315341379900_pvz079-B60","doi-asserted-by":"crossref","first-page":"476","DOI":"10.3109\/09637486.2011.636345","article-title":"Lipid-altering effects of a dietary supplement tablet containing free plant sterols and stanols in men and women with primary hypercholesterolaemia: a randomized, placebo-controlled crossover trial","volume":"63","author":"Maki","year":"2012","journal-title":"Int J Food Sci Nutr"},{"key":"2020091315341379900_pvz079-B61","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s00394-011-0297-x","article-title":"The effect of plant sterols on serum triglyceride concentrations is dependent on baseline concentrations: a pooled analysis of 12 randomised controlled trials","volume":"52","author":"Demonty","year":"2013","journal-title":"Eur J Nutr"}],"container-title":["European Heart Journal - Cardiovascular Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ehjcvp\/advance-article-pdf\/doi\/10.1093\/ehjcvp\/pvz079\/31700065\/pvz079.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ehjcvp\/article-pdf\/6\/2\/115\/33741913\/pvz079.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ehjcvp\/article-pdf\/6\/2\/115\/33741913\/pvz079.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,13]],"date-time":"2020-09-13T15:34:37Z","timestamp":1600011277000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article\/6\/2\/115\/5686388"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,24]]},"references-count":61,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2019,12,24]]},"published-print":{"date-parts":[[2020,3,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcvp\/pvz079","relation":{},"ISSN":["2055-6837","2055-6845"],"issn-type":[{"value":"2055-6837","type":"print"},{"value":"2055-6845","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,3]]},"published":{"date-parts":[[2019,12,24]]}}}